OptimizeRx (OPRX)
(Real Time Quote from BATS)
$6.57 USD
-0.06 (-0.91%)
Updated Oct 14, 2024 02:42 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for OptimizeRx Corp falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 14 | 74 | 85 | 11 | 19 |
Receivables | 37 | 22 | 25 | 18 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 2 | 6 | 4 | 1 |
Total Current Assets | 54 | 99 | 115 | 33 | 27 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 128 | 36 | 25 | 27 | 29 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 183 | 135 | 141 | 60 | 57 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 1 | 1 | 0 |
Current Portion Long-Term Debt | 2 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 3 | 3 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 4 | 6 | 7 | 4 |
Total Current Liabilities | 18 | 8 | 9 | 10 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 4 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 34 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 57 | 9 | 10 | 10 | 12 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 191 | 173 | 167 | 86 | 78 |
Retained Earnings | -64 | -47 | -35 | -36 | -33 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 127 | 126 | 131 | 50 | 45 |
Total Liabilities & Shareholder's Equity | 183 | 135 | 141 | 60 | 57 |
Total Common Equity | 127 | 126 | 131 | 50 | 45 |
Shares Outstanding | 18.10 | 17.10 | 17.70 | 15.10 | 14.10 |
Book Value Per Share | 6.99 | 7.37 | 7.42 | 3.31 | 3.18 |
Fiscal Year End for OptimizeRx Corp falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 15 | 15 | 14 | 64 |
Receivables | NA | 26 | 31 | 37 | 21 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 2 | 3 | 3 |
Total Current Assets | NA | 46 | 48 | 54 | 87 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 126 | 127 | 128 | 35 |
Deposits & Other Assets | NA | 0 | 1 | 1 | 1 |
Total Assets | NA | 173 | 176 | 183 | 124 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 2 | 2 | 1 |
Current Portion Long-Term Debt | NA | 3 | 4 | 2 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 5 | 7 | 8 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 3 | 4 | 6 | 4 |
Total Current Liabilities | NA | 15 | 17 | 18 | 8 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 4 | 4 | 4 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 32 | 32 | 34 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 52 | 54 | 57 | 8 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 196 | 194 | 191 | 176 |
Retained Earnings | NA | -75 | -71 | -64 | -60 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 121 | 123 | 127 | 116 |
Total Liabilities & Shareholder's Equity | NA | 173 | 176 | 183 | 124 |
Total Common Equity | 0 | 121 | 123 | 127 | 116 |
Shares Outstanding | 18.30 | 18.20 | 18.10 | 18.10 | 16.60 |
Book Value Per Share | 0.00 | 6.65 | 6.77 | 6.99 | 6.99 |